Semaglutide Dosing for US Patients: Avoid Compounded Vial Errors

October 1, 2026
Hands checking syringe beside anonymous medication vial

Typical initiation for semaglutide is 0.25 mg injected under the skin once weekly for the first 4 weeks, then increased roughly every 4 weeks toward a maintenance dose set by your clinician and the product label. For WEGOVY, maintenance is commonly 1.7 mg or 2.4 mg once weekly, while Ozempic tops out at 2.0 mg weekly for blood sugar control. None of this replaces an individualized prescription: dosing decisions belong to you and your prescriber, guided by the FDA label for your specific product.

TL;DR:

  • Starting doses of semaglutide are strictly 0.25 mg weekly for four weeks, with gradual increases every four weeks to reach the target dose.
  • The maximum labeled dose for WEGOVY is 1.7 or 2.4 mg weekly, while Ozempic caps at 2.0 mg weekly to optimize blood sugar control.
  • Dosing adjustments should prioritize patient tolerability, delaying escalation when side effects like nausea appear, and always follow specific timing guidelines.
  • Compounded semaglutide vials require careful calculation based on concentration in mg/mL to avoid dosing errors, as unit measurements are volume-based and vary by vial.
  • Any missed doses within five days should be taken as soon as remembered; longer gaps may necessitate starting over at a lower dose under clinician supervision.
Revive Meds
Get Clinician-Supervised GLP-1 Care
Revive Meds provides individualized medical intake, clinician oversight, and ongoing provider messaging for GLP-1 treatment.

Explore Revive Meds

Table of Contents

Wegovy and Ozempic dosing schedules side by side

Semaglutide is sold under different brand names depending on what it treats, and each has its own labeled schedule. WEGOVY is approved for chronic weight management, while Ozempic is approved for type 2 diabetes, and their escalation tables differ in top dose and intent even though both start the same way.

WEGOVY begins at 0.25 mg once weekly for the first 4 weeks. This starting dose is not meant to produce meaningful weight loss. It exists to let your body adjust before the dose climbs. From there, the WEGOVY label calls for an increase every 4 weeks: to 0.5 mg, then 1.0 mg, then 1.7 mg, arriving at a maintenance dose of either 1.7 mg or 2.4 mg once weekly depending on tolerability and your treatment goal.

Wegovy and Ozempic dosing schedules side by side — overview diagram

Ozempic follows a similar opening but a different ceiling. The Ozempic label starts at 0.25 mg weekly for 4 weeks, moves to 0.5 mg, and can rise to 1.0 mg and then 2.0 mg, with at least 4 weeks between each increase. The maximum recommended Ozempic dose is 2.0 mg once weekly, reserved for patients who need additional glycemic control.

The 4-week spacing between increases is not arbitrary. It mirrors how long it takes the drug to reach steady levels in the body and gives the gut time to adjust, which is the main reason nausea and other gastrointestinal effects tend to ease with slower escalation rather than a rapid jump to a higher dose.

Product Weeks 1-4 Weeks 5-8 Weeks 9-12 Weeks 13-16 Maintenance
WEGOVY (weight management) 0.25 mg 0.5 mg 1.0 mg 1.7 mg 1.7 mg or 2.4 mg weekly
Ozempic (type 2 diabetes) 0.25 mg 0.5 mg 1.0 mg 2.0 mg (if needed) The maximum recommended dose for Ozempic is 2.0 mg weekly

These figures come directly from the WEGOVY and Ozempic prescribing information, and a clinical review of once-weekly semaglutide backs the same initiation and 4-week escalation pattern for weight management use. Your own schedule may move slower if side effects show up, and that adjustment is normal rather than a sign something has gone wrong.

Injecting semaglutide correctly: technique, sites, and storage

Semaglutide is given as a subcutaneous injection, meaning it goes into the fatty layer just under the skin rather than into muscle or a vein. The DailyMed WEGOVY monograph lists the abdomen, thigh, and upper arm as acceptable sites, and switching among them each week helps prevent irritation at any one spot.

  • Inject into the abdomen, thigh, or upper arm, and rotate the exact spot each week.
  • Check the solution before injecting: it should look clear and colorless to pale yellow, with no cloudiness or visible particles.
  • Follow the Instructions for Use that came with your specific pen or vial, since handling differs by presentation.
  • Store according to the label, and once a pen is in use, follow its specific temperature and time limits.
  • Drop used needles and pens into a sharps container rather than a household trash bin.

Dosing day can move if needed. If you need to change your weekly injection day, the label allows it as long as at least 48 hours have passed since your last dose. Outside of that, semaglutide can be taken any time of day, with or without food, which gives most people some flexibility in fitting it into a routine.

Pro Tip: Set a recurring weekly phone reminder on injection day rather than relying on memory, since consistent weekly timing matters more for semaglutide than the exact hour you inject.

Why doses increase slowly and what to do about a missed shot

The stepwise climb from 0.25 mg to a maintenance dose is not just caution for its own sake. A clinical review of once-weekly semaglutide frames slow titration as a way to reduce gastrointestinal side effects like nausea and vomiting while keeping patients on therapy long enough to see results. Jumping straight to a higher dose tends to backfire, triggering side effects severe enough that people quit before the medication has a chance to work.

When a dose is not sitting well, the fix is usually time, not abandonment. If nausea or other side effects are hard to manage at a given step, the standard approach is:

  1. Stay at the current dose for an extra 4 weeks before attempting the next increase.
  2. Contact your clinician if symptoms persist or worsen, rather than pushing through on your own schedule.
  3. Never escalate faster than the label allows, even if you feel ready, since the interval protects against cumulative side effects.
  4. If a weekly dose is missed and it has been 5 days or less, take it as soon as you remember, then resume your regular schedule.
  5. If more than 5 days have passed, skip the missed dose and take the next one on your usual day rather than doubling up.

Missing two or more doses in a row changes the calculation. Restarting at the previous maintenance dose after an extended gap can reintroduce the same nausea and gastrointestinal discomfort that titration was designed to avoid, so many clinicians choose to reinitiate at a lower dose, sometimes back at 0.25 mg, and titrate up again. This is a judgment call your prescriber should make, not a fixed rule you apply yourself. Any severe or unusual symptoms, whether related to a missed dose or not, warrant a call to your clinician before you make any changes.

Avoiding dosing errors with compounded semaglutide vials

Compounded semaglutide is typically dispensed in multi-dose vials measured in units on a standard insulin syringe, rather than in the pre-measured pens used for branded products. That difference is where most dosing confusion starts. The FDA has warned about adverse events and dosing errors tied to compounded GLP-1 products, pointing out that units are a measure of volume, not drug mass, so a given number of units only tells you the actual dose once you know the vial’s concentration.

A unit count means nothing on its own. The FDA’s alert on unapproved GLP-1 drugs explains that compounded products lack the standardized delivery of an approved pen, which has contributed to dosing errors serious enough to require medical attention.

The math itself is simple once you have the two numbers you need: the prescribed dose in milligrams and the vial’s concentration in milligrams per milliliter. As an illustrative example, say a vial is labeled at 2.5 mg/mL and your prescribed dose is 0.5 mg. Dividing 0.5 by 2.5 gives 0.2 mL, which on a standard 100-unit insulin syringe corresponds to 20 units. Change the vial concentration and that unit count changes too, even though the milligram dose stayed the same, which is exactly the mismatch that leads to errors.

Before drawing up any compounded dose, work through this checklist:

  • Read the vial label for its exact concentration in mg/mL before drawing any dose.
  • Calculate the milliliters needed for your prescribed milligram dose, not the other way around.
  • Confirm which markings your syringe uses and double check that your calculated volume lines up with those marks.
  • Have your clinician or pharmacist verify the calculation before your first dose or after any vial change.
  • Prefer FDA-approved prefilled pens when they are accessible, since they remove this conversion step entirely.

If you do use a compounded vial, insist on a licensed prescriber and a pharmacy that is FDA-registered, and keep the conversion step in the hands of a professional whenever possible rather than relying on your own arithmetic alone. Revive Meds’ guidance on gender-specific dosing considerations for men covers this same units-to-milligram distinction in more detail for compounded concentrations, and the legal and safety context is laid out further in this explainer on compounded semaglutide.

What the label warns about, and when to call your clinician

Semaglutide carries a boxed warning tied to thyroid C-cell tumors seen in rodent studies, and it is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Your clinician should ask about thyroid history before prescribing and counsel you on symptoms like a neck lump, hoarseness, or difficulty swallowing that warrant prompt evaluation.

Gastrointestinal effects are the most common complaints, and while nausea, vomiting, and diarrhea are usually manageable, they carry a real risk when they lead to dehydration.

  • Nausea, vomiting, and diarrhea are the most frequently reported side effects, especially during dose increases.
  • Persistent vomiting or diarrhea can cause dehydration severe enough to trigger acute kidney injury, which needs urgent medical attention.
  • People with diabetes starting or adjusting semaglutide should monitor blood glucose closely, since the drug affects glycemic control directly.
  • Combining semaglutide with other semaglutide-containing products, or with other GLP-1 medications, should only happen under direct clinician guidance, since stacking doses raises the risk of the same side effects without added benefit.

Pro Tip: If vomiting or diarrhea lasts more than a day or two, call your clinician rather than waiting it out, since dehydration can escalate quickly and is one of the more serious risks tied to GLP-1 therapy.

Anyone on insulin or other diabetes medications should talk with their prescriber before starting semaglutide, since the combination can increase the risk of low blood sugar and may require dose adjustments to those other medications.

Switching forms, pregnancy, and other special situations

A few situations fall outside the standard titration path, and the label addresses each differently.

  • Switching between WEGOVY oral tablets and the injection form follows specific timing rules described in the label, and should be done under clinician direction rather than self-managed.
  • Semaglutide should be stopped before a planned pregnancy, with most clinical guidance recommending discontinuation at least two months ahead of conception, a point covered in more depth in this clinical guidance on semaglutide and pregnancy.
  • People with kidney or liver impairment should have their dosing and monitoring plan set individually by their clinician, since the label calls for added caution in these groups rather than a fixed dose adjustment.
  • Pediatric and adolescent use has its own age thresholds and label-specific rules, and falls outside general adult dosing guidance.

None of these are situations to navigate from general dosing information alone. Each one changes the risk calculation enough that a clinician needs to weigh in directly, and Revive Meds’ guidance for women covers several of these considerations in more detail for that population.

Why individualized titration matters more than the label alone

The published schedules give you a starting point, not a fixed path everyone should follow identically. In practice, plenty of people need to sit at a dose longer than the standard 4 weeks, and that is not a failure of the treatment or the patient. It is the schedule doing what it is supposed to do.

What tends to get missed is that most tolerability problems are solved by a small adjustment, not by quitting. Holding a dose for an extra month, splitting an injection to a different day, or simply waiting out a rough first week resolves far more cases than switching medications entirely. The patients who stay on therapy longest are usually the ones whose clinicians treated the schedule as a starting draft rather than a rulebook, adjusting pace based on how the person actually responded rather than how fast the label allows movement. That kind of adjustment requires someone paying attention between visits, not just at the prescription stage, which is why ongoing messaging access with a clinician matters as much as the initial prescribing decision.

— Amy

Getting clinician-supervised semaglutide without the guesswork

Many telehealth providers run semaglutide protocols through a medical intake reviewed by a licensed clinician before shipping medications, with compounds often from FDA-registered pharmacies and quick home delivery available.

Revive Meds

The conversion risks covered above, reading a vial label correctly, calculating the right volume, confirming syringe markings, are exactly what a clinician and pharmacy team should be double checking on your behalf rather than leaving to you alone. Some providers pair prescriptions with injection guidance and unlimited provider messaging, offering support for dosing concerns. Many avoid membership fees and long-term contracts, focusing on individualized protocols. If you want a dosing plan that starts with a clinician’s review instead of a guess, you can start your semaglutide intake with Revive Meds.

This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.

Sources

FAQ

Is 25 units of semaglutide a lot?

It depends entirely on the vial’s concentration, since units measure volume, not the actual milligram dose. The amount of drug delivered varies with vial concentration, which is why the FDA warns against relying on unit counts without confirming concentration first.

Can I start semaglutide at 2.5 mg?

No, 2.5 mg is far above any approved starting dose for semaglutide. Standard initiation under the WEGOVY and Ozempic labels is 0.25 mg once weekly for the first 4 weeks, with any higher dose reached only through gradual titration under clinician supervision.

Can you take more than 2.4 mg of semaglutide?

No labeled semaglutide product recommends exceeding 2.4 mg weekly, which is the highest WEGOVY maintenance dose listed in its prescribing information. Ozempic’s maximum is lower, at 2.0 mg weekly, and taking more than a clinician has prescribed raises the risk of gastrointestinal side effects without added benefit.

How many units is 0.5 mg of semaglutide?

The unit count depends entirely on the vial’s labeled concentration, so there is no single answer that applies to every compounded vial. For a vial labeled at 2.5 mg/mL, 0.5 mg works out to 0.2 mL, or 20 units on a standard 100-unit insulin syringe, but a different concentration changes that number, which is why the FDA urges checking the label every time.